Therefore, we examined the antitumor activity of the EGFR/HER2 inhibitor (gefitinib and lapatinib) combined with the IGF-1R inhibitor (linsitinib) on the ESCC. This evidence concerns the gene IGF1R and esophageal squamous cell carcinoma.